Lv1
68 积分 2024-11-14 加入
Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-Type RAS Isoforms in Codon 13 RAS-Mutant Cancers
6天前
已完结
Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer
11天前
已关闭
The next generation of antibody–drug conjugates
12天前
已完结
Application of Bioisosteres in the Design and Discovery of FDA-Approved Drugs and Advanced Clinical Candidates
1个月前
已完结
Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical Evaluation
1个月前
已完结
Pan-RAS Inhibitors: Expanding Therapeutic Potential and Evading Resistance
2个月前
已完结
Dual-payload ADCs move into first oncology clinical trials
4个月前
已完结
Exploring the next generation of antibody–drug conjugates
4个月前
已完结
Homogeneous multi-payload antibody–drug conjugates
4个月前
已完结
Targeting KRAS G12D : Advances in Inhibitor Design
4个月前
已完结
皖公网安备34019202002308
